SITC 2023 – Aulos and Xilio press on with cytokine approaches
But the groups have yet to see any responses with AU-007 and XTX202 respectively.
Interview – Coherus sees the stars aligning at last
After two years Loqtorzi is on the US market at last, and Coherus looks to its Surface acquisition to play the combo game.
ESMO 2023 – low-dose volrustomig hints at a therapeutic window
But efficacy still needs to go up, as several groups try to combine PD-1 and CTLA-4 using differing approaches.
ESMO 2023 – Perla gives Jemperli combos more backing
The numerical survival benefit versus Keytruda underperform’s Merck’s phase 3 study, but there’s a possible reason for that.
